Metformin alleviates bone loss in ovariectomized mice through inhibition of autophagy of osteoclast precursors mediated by E2F1
Authors:
Open Access
- 25 October 2022
- journal article
- research article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 20 (1) , 1-18
Abstract
Background: Postmenopausal bone loss, mainly caused by excessive bone resorption mediated by osteoclasts, has become a global public health burden. Metformin, a hypoglycemic drug, has been reported to have beneficial effects on maintaining bone health. However, the role and underlying mechanism of metformin in ovariectomized (OVX)-induced bone loss is still vague. Results: In this study, we demonstrated for the first time that metformin administration alleviated bone loss in postmenopausal women and ovariectomized mice, based on reduced bone resorption markers, increased bone mineral density (BMD) and improvement of bone microstructure. Then, osteoclast precursors administered metformin in vitro and in vivo were collected to examine the differentiation potential and autophagical level. The mechanism was investigated by infection with lentivirus-mediated BNIP3 or E2F1 overexpression. We observed a dramatical inhibition of autophagosome synthesis and osteoclast formation and activity. Treatment with RAPA, an autophagy activator, abrogated the metformin-mediated autophagy downregulation and inhibition of osteoclastogenesis. Additionally, overexpression of E2F1 demonstrated that reduction of OVX-upregulated autophagy mediated by metformin was E2F1 dependent. Mechanistically, metformin-mediated downregulation of E2F1 in ovariectomized mice could downregulate BECN1 and BNIP3 levels, which subsequently perturbed the binding of BECN1 to BCL2. Furthermore, the disconnect between BECN1 and BCL2 was shown by BNIP3 overexpression. Conclusion: In summary, we demonstrated the effect and underlying mechanism of metformin on OVX-induced bone loss, which could be, at least in part, ascribed to its role in downregulating autophagy during osteoclastogenesis via E2F1-dependent BECN1 and BCL2 downregulation, suggesting that metformin or E2F1 inhibitor is a potential agent against postmenopausal bone loss.Keywords
Funding Information
- National Science Foundation of China (No. 82002313, No. 82072444)
- National Key Research & Development Program of China (No.2018YFC2001502, 2018YFB1105705)
- Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration (No.2020kqhm008)
This publication has 75 references indexed in Scilit:
- HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosisProceedings of the National Academy of Sciences, 2013
- Induction of autophagy is essential for monocyte-macrophage differentiationBlood, 2012
- Autophagy Proteins Regulate the Secretory Component of Osteoclastic Bone ResorptionDevelopmental Cell, 2011
- Osteoclast precursor differentiation by MCPIP via oxidative stress, endoplasmic reticulum stress, and autophagyJournal of Molecular Cell Biology, 2011
- The Beclin 1 network regulates autophagy and apoptosisCell Death & Differentiation, 2011
- The RB-E2F1 Pathway Regulates AutophagyCancer Research, 2010
- AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone massBone, 2010
- Autophagy fights disease through cellular self-digestionNature, 2008
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- Osteoclast differentiation and activationNature, 2003